Amstutz U - Search Results

1

Come a long way, still a ways to go: from predicting and preventing fluoropyrimidine toxicity to increased efficacy?

Hamzic S, Amstutz U, Largiadèr CR. Hamzic S, et al. Among authors: amstutz u. Pharmacogenomics. 2018 Jun 1;19(8):689-692. doi: 10.2217/pgs-2018-0040. Epub 2018 May 22. Pharmacogenomics. 2018. PMID: 29783877 Free article. No abstract available.

2

Population transcriptomics of life-history variation in the genus Salmo.

Giger T, Excoffier L, Amstutz U, Day PJ, Champigneulle A, Hansen MM, Kelso J, Largiadèr CR. Giger T, et al. Among authors: amstutz u. Mol Ecol. 2008 Jul;17(13):3095-108. doi: 10.1111/j.1365-294X.2008.03820.x. Epub 2008 Jun 3. Mol Ecol. 2008. PMID: 18522696

3

Hypermethylation of the DPYD promoter region is not a major predictor of severe toxicity in 5-fluorouracil based chemotherapy.

Amstutz U, Farese S, Aebi S, Largiadèr CR. Amstutz U, et al. J Exp Clin Cancer Res. 2008 Oct 20;27(1):54. doi: 10.1186/1756-9966-27-54. J Exp Clin Cancer Res. 2008. PMID: 18937829 Free PMC article.

4

Dihydropyrimidine dehydrogenase gene variation and severe 5-fluorouracil toxicity: a haplotype assessment.

Amstutz U, Farese S, Aebi S, Largiadèr CR. Amstutz U, et al. Pharmacogenomics. 2009 Jun;10(6):931-44. doi: 10.2217/pgs.09.28. Pharmacogenomics. 2009. PMID: 19530960 Free article.

5

Sequence capture and next-generation resequencing of multiple tagged nucleic acid samples for mutation screening of urea cycle disorders.

Amstutz U, Andrey-Zürcher G, Suciu D, Jaggi R, Häberle J, Largiadèr CR. Amstutz U, et al. Clin Chem. 2011 Jan;57(1):102-11. doi: 10.1373/clinchem.2010.150706. Epub 2010 Nov 10. Clin Chem. 2011. PMID: 21068339 Free article.

6

Dihydropyrimidine dehydrogenase gene as a major predictor of severe 5-fluorouracil toxicity.

Amstutz U, Froehlich TK, Largiadèr CR. Amstutz U, et al. Pharmacogenomics. 2011 Sep;12(9):1321-36. doi: 10.2217/pgs.11.72. Pharmacogenomics. 2011. PMID: 21919607 Free article. Review.

7

LC-MS/MS method for simultaneous analysis of uracil, 5,6-dihydrouracil, 5-fluorouracil and 5-fluoro-5,6-dihydrouracil in human plasma for therapeutic drug monitoring and toxicity prediction in cancer patients.

Büchel B, Rhyn P, Schürch S, Bühr C, Amstutz U, Largiadèr CR. Büchel B, et al. Among authors: amstutz u. Biomed Chromatogr. 2013 Jan;27(1):7-16. doi: 10.1002/bmc.2741. Epub 2012 Mar 27. Biomed Chromatogr. 2013. PMID: 22454320

8

Higher frequency of genetic variants conferring increased risk for ADRs for commonly used drugs treating cancer, AIDS and tuberculosis in persons of African descent.

Aminkeng F, Ross CJ, Rassekh SR, Brunham LR, Sistonen J, Dube MP, Ibrahim M, Nyambo TB, Omar SA, Froment A, Bodo JM, Tishkoff S, Carleton BC, Hayden MR; Canadian Pharmacogenomics Network for Drug Safety Consortium. Aminkeng F, et al. Pharmacogenomics J. 2014 Apr;14(2):160-70. doi: 10.1038/tpj.2013.13. Epub 2013 Apr 16. Pharmacogenomics J. 2014. PMID: 23588107 Free PMC article.

9

Clinical importance of risk variants in the dihydropyrimidine dehydrogenase gene for the prediction of early-onset fluoropyrimidine toxicity.

Froehlich TK, Amstutz U, Aebi S, Joerger M, Largiadèr CR. Froehlich TK, et al. Among authors: amstutz u. Int J Cancer. 2015 Feb 1;136(3):730-9. doi: 10.1002/ijc.29025. Epub 2014 Jun 27. Int J Cancer. 2015. PMID: 24923815 Free article.

10

Polymorphisms in MIR27A Associated with Early-Onset Toxicity in Fluoropyrimidine-Based Chemotherapy.

Amstutz U, Offer SM, Sistonen J, Joerger M, Diasio RB, Largiadèr CR. Amstutz U, et al. Clin Cancer Res. 2015 May 1;21(9):2038-44. doi: 10.1158/1078-0432.CCR-14-2817. Epub 2015 Feb 5. Clin Cancer Res. 2015. PMID: 25655103

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

63 results

Search Page